Ibnsina Pharma reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was EGP 5,332.8 million compared to EGP 4,756.41 million a year ago. Net income was EGP 59.38 million compared to EGP 50.37 million a year ago. Basic earnings per share from continuing operations was EGP 0.0429 compared to EGP 0.0343 a year ago.